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Autism spectrum disorder (ASD) and intellectual disability (ID) can be caused by mutations in a large number of
genes. One example is SHANK3 on the terminal end of chromosome 22q. Loss of one functional copy of SHANK3
results in 22q13 deletion syndrome or Phelan-McDermid syndrome (PMS) and causes a monogenic form of ASD
and/or ID with a frequency of 0.5% to 2% of cases. SHANK3 is the critical gene in this syndrome, and its loss results
in disruption of synaptic function. With chromosomal microarray analyses now a standard of care in the assessment
of ASD and developmental delay, and with the emergence of whole exome and whole genome sequencing in this
context, identification of PMS in routine clinical settings will increase significantly. However, PMS remains a rare disorder,
and the majority of physicians have never seen a case. While there is agreement about core deficits of PMS, there have
been no established parameters to guide evaluation and medical monitoring of the syndrome. Evaluations must include
a thorough history and physical and dysmorphology examination. Neurological deficits, including the presence of
seizures and structural brain abnormalities should be assessed as well as motor deficits. Endocrine, renal, cardiac, and
gastrointestinal problems all require assessment and monitoring in addition to the risk of recurring infections, dental
and vision problems, and lymphedema. Finally, all patients should have cognitive, behavioral, and ASD evaluations. The
objective of this paper is to address this gap in the literature and establish recommendations to assess the medical,
genetic, and neurological features of PMS.
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Introduction
Gene discovery approaches, followed by functional ana-
lysis of model systems, have elucidated the neurobiology
of several genetic subtypes of autism spectrum disorder
(ASD). ASD can now be conceived of as having many
distinct genetic risk genes and one example is SHANK3
on terminal chromosome 22q. Studies indicate that loss
of one functional copy (haploinsufficiency) of SHANK3* Correspondence: alexander.kolevzon@mssm.edu
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unless otherwise stated.through deletion or mutation causes a monogenic form of
ASD with a frequency of at least 0.5% of ASD cases [1-7].
The rate of SHANK3 loss in children with moderate to
profound intellectual disability (ID) appears to be up to
2% [1,6]. SHANK3 is the critical gene in this syndrome
[2,8], and its loss is sufficient to cause Phelan-McDermid
syndrome (PMS; OMIM ID 606232). SHANK3 encodes a
scaffolding protein in the postsynaptic density of gluta-
matergic synapses and is known to play a critical role in
synaptic function [9]. Although SHANK3 deletions and
mutations account for a relatively small proportion of
ASD and ID cases, recent evidence suggests that many dif-
ferent genetic causes of ASD and ID converge on several
common pathways, including the SHANK3 pathway
[10,11]. Using Shank3-deficient mice, specific deficits inal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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have been documented [12-17]. Interestingly, reversal of
synaptic deficits has been shown with an experimental
therapeutic (insulin-like growth factor-1; IGF-1) in mouse
[18] and human neuronal models [19]. With chromosomal
microarray now recommended as a standard of care for
the assessment of ASD [20-23], it is expected that identifi-
cation of PMS will increase significantly in routine clinical
settings. To date, about 1,200 cases have been identified
worldwide according to the Phelan-McDermid Syndrome
Foundation, yet few physicians have encountered the syn-
drome. While some clinical guidelines exist [24-28], com-
prehensive medical assessment parameters have yet to be
developed.
Clinically, there have been at least 13 case series pub-
lished in the literature that describe approximately 584 af-
fected individuals (see Tables 1 and 2), although several
studies present overlapping cases and the majority of data
has been collected using parent surveys [27,29-40]. Re-
ports highlight a broad and clinically heterogeneous
phenotype; clinical features consistently reported include
global developmental delay, absent or severely delayed
speech, autistic features, minor dysmorphic features, and
hypotonia. Affected individuals are more likely to suffer
from medical complications, such as gastrointestinal dis-
ease, renal abnormalities, upper respiratory tract infec-
tions, and seizures. Brain MRI studies suggest a higher
than expected prevalence of arachnoid cysts, ventriculo-
megaly, dysmyelination, and morphological changes of the
corpus callosum [27,30,36,37,41]. Recently, several case re-
ports have also proposed a putative association between
PMS and atypical bipolar disorder and progressive loss of
skills during adolescence or adulthood [29,42,43]. Com-
prehensive mapping of the phenotype using systematic
and prospective assessment was recently reported in a
sample of 32 subjects highlighting the high prevalence of
ASD in these patients, at 84% [37].
Several studies have also examined genotype-
phenotype correlations with conflicting results.
[31-33,35,37,39,40,44,45]. Despite small sample sizes
and methodological challenges, correlations have been
observed between larger deletion sizes and minor dys-
morphic features [31,37,44], number of medical comor-
bidities [37], the Developmental Profile [45,46], hypotonia
[33,44], and the absence of an ASD diagnosis [44]. In con-
trast to the latter study, another study found that larger
deletion sizes were associated with more severe social-
communication impairments related to ASD [37], whereas
others have found no association between deletion size
and phenotypic severity [32,35].
While there is agreement about core deficits of PMS,
there have been no established parameters to guide
evaluation and medical monitoring of the syndrome.
The objective of this paper is to make recommendationsto assess the medical, genetic, and neurological features
of PMS.
Clinical genetics
Genetic testing is necessary to confirm the presence of
deletions or mutations in SHANK3. Chromosomal micro-
array analysis (CMA) should be done as a first-tier work-
up for any child with ASD or developmental delays
[20-23]. CMA will ascertain the majority of PMS cases
which most often result from deletions or other structural
rearrangements resulting in copy number loss of varying
size on 22q13 but will not identify patients with patho-
genic SHANK3 variants or smaller intragenic deletions or
duplications which disrupt gene function [30]. Deletions
at 22q13 occur de novo in the majority of patients
although in 20% of cases, a parent carries a balanced re-
arrangement [45], hence there is significant risk of recur-
rence in some families. For this reason, chromosome
analysis should be performed in conjunction with positive
CMA findings to explore the presence of ring chromo-
some 22 and translocations. Biological parents should be
tested with fluorescence in situ hybridization (FISH) to
rule out a translocation or inversion in order to determine
heritability and risk of recurrence within families. A bal-
anced translocation or inversion involving chromosome
22 in a parent significantly increases the risk of recur-
rence in families and siblings of the proband should be
tested when relevant [47-50]. There have been several re-
ports of probands with apparently de novo deletions with
siblings with identical deletions, likely resulting from
germline mosaicism in a parent [4,42,51]. Thus, although
the recurrence risk for future pregnancies is low for ap-
parently de novo deletions, it is marginally greater than in
the general population because parents may have germ-
line mosaicism. Finally, for cases where PMS is part of the
differential diagnosis, Sanger or next generation sequen-
cing should be used to test for SHANK3 mutations if
CMA and karyotyping are unrevealing. In addition, it
should be noted that several clinical laboratories offer aut-
ism sequencing panels which include the SHANK3 gene.
In this situation, it is important to determine whether the
clinical laboratory offers complete sequencing of the
SHANK3 gene. Indeed, SHANK3 is one of the most GC-
rich genes in the genome, and reliable sequencing re-
quires considerable optimization. Supplemental testing by
multiplex ligation-dependent probe amplification (MLPA)
or other dosage-sensitive methods for detection of smaller
intragenic deletions and duplications below the resolution
of CMA may be considered as some clinical laboratories
will include these after a negative sequencing result.
Clinical genetics evaluations and dysmorphology exams
should be performed by a clinical geneticist to assess
growth, pubertal development, head size, craniofacial fea-
tures, digits, extremities, chest, spine, skin, and screen for































n = 7 n = 37 n = 33 n = 11 n = 9 n = 30 n = 107 n = 13 n = 43 n = 7 n = 54 n = 32 n = 201
Sparse hair/abnormal whorl n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 16% (5/32) n/a 16
Macrocephaly n/a n/a n/a n/a n/a 7% (2/30) n/a n/a 21% (9/43) n/a 23% (11/47) 31% (10/32) 18% (20/110) 17
Microcephaly n/a n/a n/a n/a n/a 13% (4/30) n/a n/a 11% (5/43) n/a 14% (6/42) 6% (2/32) 11% (12/110) 12
Dolichocephaly 86% (6/7) 57% (21/37) n/a n/a 0% (0/9) 23% (7/30) 30% (32/107) n/a n/a n/a 30% (16/54) 25% (8/32) 32% (36/113) 37
Periorbital fullness n/a n/a n/a 45% (5/11) n/a 60% (18/30) n/a n/a n/a n/a n/a 25% (8/32) 55% (60/109) 46
Epicanthal folds 57% (4/7) 41% (15/37) n/a 73% (8/11) n/a 37% (11/30) 30% (32/107) 70% (9/13) n/a n/a n/a 31% (10/32) 47% (52/111) 48
Ptosis 43% (3/7) 57% (21/37) n/a n/a 0% n/a 23% (25/107) n/a n/a n/a n/a 3% (1/32) 47% (53/112) 29
Deep set eyes n/a n/a n/a n/a n/a n/a n/a n/a n/a 14% (1/7) n/a 6% (2/32) 31% (34/111) 19
Long eyelashes n/a n/a n/a 45% (5/11) n/a 37% (11/30) n/a n/a n/a n/a n/a 44% (14/32) 93% (105/113) 58
Hypertelorism n/a n/a n/a 36% (4/11) n/a 17% (5/30) n/a n/a n/a n/a n/a 13% (4/32) n/a 22
Wide nasal bridge n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 16% (5/32) n/a 16
Bulbous nose n/a n/a n/a n/a n/a 80% (24/30) n/a 70% (9/13) n/a n/a 61% (33/54) 47% (15/32) n/a 65
Low set ears n/a n/a n/a n/a n/a 7% (2/30) n/a n/a n/a 14% (1/7) n/a 3% (1/32) n/a 5
Ear anomalies 86% (6/7) 65% (24/37) 82% (27/33) 27% (3/11) 67% (6/9) 73% (22/30) 54% (58/107) 70% (9/13) n/a n/a n/a 41% (13/32) n/a 63
Full lips n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 31% (10/32) n/a 31
High arched palate n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 25% (8/32) 47% (49/104) 36
Long philtrum n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 16% (5/32) n/a 16
Malocclusion/widely
spaced teeth
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 19% (6/32) n/a 19
Micrognathia n/a n/a n/a n/a n/a 10% (3/30) n/a n/a n/a n/a n/a 13% (4/32) n/a 12
Full cheeks n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 25% (8/32) n/a 25
Malar hypoplasia n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 9% (3/32) n/a 9
Flat midface n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 3% (1/32) n/a 3
Pointed chin n/a 62% (23/37) n/a n/a 56% (5/9) n/a 27% (29/107) n/a n/a n/a n/a 22% (7/32) 52% (58/111) 44
Fifth finger clinodactyly n/a 14% (5/37) n/a n/a n/a n/a n/a n/a n/a n/a n/a 9% (3/32) n/a 12
Large fleshy hands n/a 68% (25/37) n/a n/a 56% (5/9) 47% (14/30) 33% (35/107) 46% (6/13) n/a n/a 55% (29/53) 53% (17/32) 63% (71/112) 53
Hypoplastic/dysplastic
nails
n/a 78% (29/37) n/a 27% (3/11) 56% (5/9) 3% (1/30) 36% (39/107) 23% (3/13) n/a n/a 75% (40/53) 34% (11/32) 73% (81/111) 45
Hyper-extensibility n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 25% (8/32) 61% (68/111) 86
Abnormal spine curvature n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 22% (7/32) n/a 22
Sacral dimple n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 37% (19/52) 13% (4/32) n/a 25
Syndactyly of
toes 2 and 3
n/a 38% (14/37) n/a 45% (5/11) n/a 43% (13/30) 23% (25/107) n/a n/a n/a n/a 9% (3/32) 48% (53/110) 34
n/a = not available.

















































n = 7 n = 37 n = 33 n = 11 n = 9 n = 30 n = 107 n =13 n = 43 n = 7 n = 54 n = 32 n = 201
Hypotonia 100% (7/7) 97% (36/37) 82% (27/33) 82% (9/11) 89% (8/9) 47% (14/30) 86% (92/107) 31% (4/13) n/a 29% (2/7) 80% (48/60) 75% (24/32) 75% (82/110) 73
Sleep disturbance n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 41% (13/32) 46% (12/26) 44
Gastroesophageal
reflux
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 44% (14/32) 42% (62/149) 43
Increased pain
tolerance
n/a n/a n/a 0% n/a 10% (3/30) 31% (33/107) n/a n/a n/a n/a 88% (28/32) 77% (131/170) 42
Constipation/
diarrhea
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 38% (12/32) 41% (11/27) 40
Brain imaging
abnormalities




n/a n/a n/a n/a n/a n/a n/a 8% (1/13) n/a n/a n/a 53% (17/32) n/a 30
Renal abnormalities n/a n/a n/a n/a n/a 17% (5/30) n/a n/a n/a n/a n/a 38% (12/32) 26% (39/148) 27
Lymphedema 29% (2/7) n/a n/a n/a n/a n/a n/a 23% (3/13) n/a n/a n/a 22% (7/32) 24% (26/108) 25
Seizures (febrile
and/or non-febrile)
14% (1/7) 27% (10/37) 24% (8/33) 27% (3/11) n/a 17% (5/30) 23% (25/107) 31% (4/13) n/a 14% (1/7) 19% (10/54) 41% (13/32) 27% (41/151) 24
Esotropia/
strabismus
n/a n/a n/a n/a n/a 13% (4/30) n/a n/a n/a 14% (1/7) 25% (13/53) 6% (2/32) 26% (29/109) 17
Short stature/
delayed growth




14% (1/7) n/a 18% (6/33) n/a n/a 7% (2/30) n/a n/a 11% (5/43) n/a 13% (5/40) 3% (1/32) 9% (9/96) 11
Cardiac defects n/a n/a n/a n/a n/a 13% (4/30) n/a n/a n/a n/a n/a 3% (1/32) n/a 8
Precocious or
delayed puberty
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0% (0/32) 12% (15/121) 6
Hypothyroidism n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 3% (1/32) 6% (7/121) 5
n/a = not available.
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defects). Most patients with PMS have at least one dys-
morphic feature, although none are specific. The most
common features are large fleshy hands, long eyelashes,
pointed chin, prominent/dysplastic ears, bulbous nose,
full lips, hypoplastic/dysplastic nails, and dolichocephaly
(see Figure 1 and Table 1). All images are provided with
guardian consent.
Cognitive/behavioral assessment
All patients with PMS should be referred to centers with
expertise in developmental disorders for comprehensive
cognitive, behavioral, and ASD evaluations. To date, clin-
ical methods to assess the prevalence of ASD in PMS
have varied significantly. Studies that prospectively evalu-
ate ASD suggest rates from 0% (0/8) [36], 44% (12/27)
[31], 60% (3/5) [30], 84% (27/32) [37] to 94% (17/18)
[27]. Of these studies, only Soorya and colleagues [37]
used gold-standard diagnostic instruments—the Autism
Diagnostic Interview-Revised and the Autism Diagnostic
Observation Schedule. Given the limitations of ASD-
specific diagnostic tools in individuals with significant ID,
integrating careful clinical evaluation, caregiver reports,
and structured direct observation is necessary in PMS.
Cognitive assessments must likewise use standardized in-
struments appropriate for individuals with significant
language delays and intellectual disability. Referrals for
speech and language therapy, physical therapy, and oc-
cupational therapy evaluations should also be made. A
diagnosis of ASD may aid in designing individualized
educational and related service treatment plans and in
justifying services through the board of education andFigure 1 Images of individuals with Phelan-McDermid syndrome illus
eyelashes, bulbous nose, and pointed chin. All images are provided witinsurance providers. Therapies should be delivered early
and intensively given the severity of disability in many
affected children. Because of significant learning and at-
tention deficits in these patients, increased frequency of
treatment with shorter duration of sessions may be fa-
vorable. While the cognitive and behavioral assessment
of affected individuals is critical, it is nevertheless con-
sidered outside of the scope of this paper and will be ad-
dressed in subsequent recommendations.
Neurology
Neurological examinations should be conducted to evalu-
ate gross motor skills and gait, fine motor coordination,
cranial nerves, and deep tendon reflexes. In PMS, evidence
supports the high prevalence of hypotonia (see Table 2),
delays in achieving motor milestones, and inability to
ambulate, among other motor deficits [27,30-34,36,37].
Feeding difficulties are a common early sign, possibly
associated with hypotonia. Gait is almost uniformly af-
fected in PMS, and abnormalities include steppage gait,
toe walking, and variable degrees of broad-based ataxic
gait. Careful assessment of this domain is important, as is
appropriate referrals for pediatric physiatry, physical
therapy, and orthopedics to explore the possibility of
various interventions, including orthotics and bracing.
Abnormality of posture, motor coordination and motor
planning, though not specific to PMS, are almost invariably
seen. There is also an increased risk of scoliosis. Given the
broad array of motor deficits, low muscle tone and related
feeding problems, physical, occupational, and feeding ther-
apy should be initiated as early as possible. Screening
for neuromuscular scoliosis should be performed at everytrating common dysmorphic facial features, including long
h guardian consent.
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http://www.jneurodevdisorders.com/content/6/1/39routine visit. Head growth may also be abnormal, and
some patients have macrocephaly (see Table 1); head cir-
cumference measurements should be performed routinely
in PMS up to age 36 months.
Seizure assessment
Neurological phenotypic features are in need of further
clarification in PMS, and few studies have reported elec-
troencephalography (EEG) results. Most descriptions of
PMS report higher than expected rates of seizure disor-
ders; however, recording methods are not consistent and
findings have not been well replicated. EEG recordings
have not been prospectively collected in published studies
of PMS, although existing case series report on the preva-
lence of seizure disorders using retrospective review and
parent survey methods [27,30,31,33,36,37,39]. Prevalence
estimates of seizure disorders range from 0% (0/8) [36] to
31% (4/13) [30], depending on the study. In a recent
study, 41% (13/32) of participants had clinical seizures re-
ported by parents, including 22% (7/32) with febrile sei-
zures only, one participant with complex febrile seizures,
and another patient who required temporal lobectomy
due to uncontrolled seizure disorder [37]. Seizure disor-
ders can be highly debilitating for affected children and
families. Seizures have been associated with regression in
some cases [36], in addition to at least one report of mor-
tality due to seizure-induced aspiration [2]. Seizures have
not been intractable in most patients with PMS, but there
is no information about whether certain anticonvulsant
medications are more effective than others for these indi-
viduals. Overnight video-EEG is therefore recommended
using the standard 10–20 system and 64 inputs of online
spike and seizure detection programs for automated de-
tection. Brief recordings may be inadequate to detect
changes in some patients and sedation may be required
to get reliable recordings. While an overnight EEG is not
always needed to establish the diagnosis, it can be helpful
in determining the type of seizures and assist in treatment
decisions. There should also be a low threshold for re-
peating an EEG with signs of behavioral changes or re-
gression, including loss of motor skills.
Brain imaging
Most descriptions of PMS report higher than expected
rates of structural brain changes. Among the published
case series, a total of 59 patients have had brain imaging,
either through prospective assessment [30,36,52] or med-
ical record review [34,37]. Brain abnormalities were evi-
dent in 73% (43/59) of the cases, ranging from 44% (4/11)
[34] to 100% (10/10) [52]. Changes included thinning or
hypoplasia of the corpus callosum in 36% of cases (21/59);
white matter changes such as delayed myelination, gener-
alized white matter atrophy, and nonspecific white matter
hyperintensities in 39% (23/59); ventricular dilatation in32% (19/59), and interventricular, cerebellar, or temporal
sylvian arachnoid cysts in 14% (8/59). The most recent
prospective study specifically examined cerebellar malfor-
mations in ten patients with PMS using magnetic brain
imaging (MRI) and found evidence of cerebellar vermis
hypoplasia in six subjects, including an enlarged cisterna
magna in five [52]. There have also been several patients
with neurofibromatosis type 2 (NF2) reported in the lit-
erature who have ring chromosome 22 with NF2 features
such as multiple intracranial meningiomas or vestibular
schwannomas [53,54]. Overall, there remains a paucity of
data on the abnormal neural systems underlying this syn-
drome. Given the high prevalence of structural brain
changes and that little is known about the neurobiology
associated with PMS, brain imaging is recommended and
routine monitoring may be indicated in some cases, de-
pending on the abnormality. Specifically, new assessments
of individuals affected with PMS should include structural
MRI to assess morphology and to rule out the presence of
cysts, and cerebellar, white matter, and corpus callosum
abnormalities. It remains to be determined how frequently
patients with PMS should have an MRI and how often
monitoring should occur when indicated. While sedation
is likely required to acquire meaningful imaging studies,
the risks of the procedure must be balanced with the po-
tential benefit, especially in the absence of clinical signs
suggestive of structural pathology.
Endocrinology
There are no systematic studies describing endocrine ab-
normalities in patients with PMS. There have been reports
of both short stature [27,29-31,33,37,40] and accelerated
growth [26,27,35,41]. In a focused analysis of growth in 55
patients previously described by the Greenwood Genetic
Center, Rollins [38] reported a larger than expected per-
centage of patients having short (11%) and tall (11%) stat-
ure (<5th percentile and >95th percentile, respectively),
although the majority (78%) fell within the normal range.
Short stature, in particular, has been specifically associated
with ring chromosome 22 in some reports [30,31,33], al-
though this is not a consistent finding in the literature [37].
Head circumference has also been specifically examined in
several studies [31,37-40], and individuals with PMS are
more likely to have either microcephaly [(<3rd percentile)
(6%–14% of cases, depending on the study) or macroceph-
aly [(>97th percentile)(7%–31% of cases)]. Hypothyroidism
was present in 1 of 32 (3%) patients in one study [37] and
7 of 121 (6%) in another [39]. Hypertrichosis has also been
reported in at least two subjects [37,55]. Finally, there has
been one case report of central diabetes insipidus in a 2-
day old infant worth noting given what little is published
about endocrine abnormalities in PMS [56].
Endocrine abnormalities should be considered in all
children with PMS and assessed when clinically indicated.
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index (BMI) measurement and should be carefully
assessed as children with PMS may have restricted diets
and may ingest non-food items. Behavioral changes con-
sistent with thyroid dysregulation should also be consid-
ered, including changes in activity level, cognition, or
motor skills, and thyroid panels should be obtained to
rule out hypothyroidism. As children get older, the possi-
bility of early or late puberty should also be explored and
monitored if necessary. Incomplete puberty such as pre-
mature adrenarche or premature thelarche should be
examined as it would be for all children. Only precocious
puberty has been reported in one study as occurring in
15 of 121 cases (12%) [39]. Menstruation can be particu-
larly confusing and distressing for individuals with PMS,
and hormonal cycling may contribute to behavioral
changes in some children. Referral to endocrinology
should be facilitated if specific endocrine abnormalities
appear.
Nephrology
Renal abnormalities are considered relatively common in
PMS, with reports suggesting rates as high as 38% [37],
but few studies have systematically examined the preva-
lence and none have used prospective methods. On com-
prehensive medical record review of 32 patients in one
study [37], renal abnormalities included vesicoureteral re-
flux (13%), hydronephrosis (13%), renal agenesis (6%),
dysplastic kidney (3%), and horseshoe kidneys and pye-
lectasis (3%). Another study documented renal problems
in 39 of 148 cases (26%), including vesicoureteral reflux
(14%), frequent urinary tract infections (8%), polycystic
kidney (5%), duplicate kidney (1%), and dilated renal pel-
vis (5%) [39]. In the only other study to specifically report
the prevalence of renal abnormalities, they were de-
scribed in the context of genitourinary abnormalities in
general, with 17% of patients affected with neonatal urin-
ary infection and malformed clitoris, vesicoureteral re-
flux, unilateral multicystic kidney, and “partial renal
failure” of unknown cause [31]. In at least one child, a
unilateral multicystic kidney and Wilms’ tumor in the
contralateral, unaffected kidney was detected using pre-
natal ultrasound [57]. As some of these genitourinary ab-
normalities may result in clinical disease and require
treatment, it is recommended that all individuals with
PMS have routine blood pressure measurement and renal
and bladder sonography performed at the time of diagno-
sis and, if the sonogram is abnormal, be referred to a
pediatric nephrologist or urologist for monitoring or
treatment. Fetal sonography should not substitute for this
study, as it is usually not performed after renal develop-
ment is complete. Because sonography may be normal in
cases of vesicoureteral reflux, urinary tract infection at a
young age or recurrent urinary tract infections shouldalso prompt nephrology or urology referral. Finally, for
those with abnormal renal or bladder sonography or high
blood pressure, urinalysis and kidney function blood tests
(e.g., urea, creatinine, and electrolytes) should be ob-
tained as the patient is being referred to expert care for
additional guidance about specific ongoing monitoring
recommendations.
Cardiology
The prevalence of congenital heart defects (CHD) in PMS
is highly variable. Phelan and McDermid (2011) report
CHD in more than 25% of patients; the most common re-
ported defects include tricuspid valve regurgitation, atrial
septal defect, patent ductus arteriosus, and total anomal-
ous pulmonary return [24,41]. Soorya and colleagues [37]
reported only one case with CHD (aortic regurgitation) in
their series of 32 patients (3%), and Jeffries and colleagues
[31] reported 4 of 30 (13%) cases to have CHD, two with
patent ductus arteriosus and two with total anomalous
pulmonary venous return. These reports are based on
retrospective chart reviews and parent questionnaires,
and there are no published data of systematic prospective
evaluations for CHD in patients with PMS using standard
of care methods. Because patients with PMS may have as-
sociated CHD that would necessitate medical and/or sur-
gical intervention, we recommend a standard cardiac
evaluation inclusive of a detailed exam, echocardiography,
and electrocardiography as part of the initial evaluation in
all patients with PMS.
Gastroenterology
Gastrointestinal symptoms are common in PMS and in-
clude gastroesophageal reflux disease (GERD), constipa-
tion, and diarrhea [27,37,39,41]. Rates are not consistently
documented, but parent interview and medical record re-
view of 32 cases suggest that GERD occurs in 44% of
cases and constipation and/or diarrhea in 38% [37]. An-
other study reported similar rates, with 62 of 149 patients
(42%) suffering from GERD and 11 of 27 (41%) from con-
stipation [39]. Cyclic vomiting has also been described in
several patients [25,41]. Feeding difficulties are likewise
common [30,37] and may be related to low muscle tone.
There have also been two reported cases of fulminant
autoimmune hepatitis in girls with PMS [58,59]. Gastro-
intestinal symptoms can be highly distressing and may
manifest as appetite or behavioral changes in patients
who cannot describe or identify their discomfort. In-
creased pain tolerance in PMS may further complicate
the diagnosis of gastrointestinal disorders. Any change in
appetite or behavior should raise suspicion of gastrointes-
tinal distress. Dietary changes and bowel regimens should
be considered with evidence of constipation and GERD
may be treated empirically, depending on symptom pat-
terns. Finally, chewing of non-food items and pica has
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chewing and pica may require the attention of a gastro-
enterologist and a referral for behavioral therapy.
Primary care/developmental pediatrics
In addition to the multitude of specialized medical fea-
tures characteristic of PMS, affected individuals are also
prone to immune system dysfunction, including recurring
ear and upper respiratory tract infections, seasonal aller-
gies, food allergies, and asthma [30,37,39]. Repeated
upper respiratory tract infections in PMS may be related,
at least partially, to low muscle tone and subsequent
problems with airway and sputum clearance. There is also
evidence from animal studies that SHANK3 protein may
play a role in immune function, including immune cell
signal transduction [60]. Children with PMS may suffer
from immunological dysfunction based on case reports of
autoimmune hepatitis [58,59], atopic dermatitis [61], and
recurring staphylococcus skin infections with a history of
cellulitis [37]. Sarasua and colleagues [39] found cellulitis
in 9 out of 137 (7%) patients. These conditions should be
managed as they would in any other child, but recogniz-
ing them may be more challenging in PMS and warrant
having a low threshold of suspicion for infections of all
types. In addition, as with any child with developmental
delays, early and aggressive referral to pediatric audiology
and ophthalmology is important, especially as there have
been case reports of PMS patients having hearing prob-
lems and vision problems including strabismus, myopia
[27,37,39], and retinitis pigmentosa in one case [32].
Lymphedema has also been reported in the literature,
including in up to 24% of cases in one study [39] and
represents an especially troubling symptom for pa-
tients [27,30,35,37,39]. Routine management is war-
ranted although benefits can be challenging to achieve.
Compression boots, pneumatic pumps, or referral to vas-
cular surgery may be considered in some cases. Thermo-
regulatory problems have also been described, including
decreased perspiration and heat intolerance. Finally, den-
tal abnormalities such as malocclusion, are common and
can be quite severe in some cases [37,41]. Orthodontic or
surgical correction of malocclusion may be considered to
reduce the risk of tooth decay and periodontal disease or
relieve pressure on the temporomandibular joint.
Conclusions
Phelan-McDermid syndrome is a complex and heteroge-
neous syndrome. While considered rare, the advent of ad-
vanced genetic analytic methods into clinical practice will
likely identify more cases, and clinicians will require
knowledge about appropriate assessment, and eventually
treatment. CMA is the first tier in genetic analysis in
addition to chromosome analysis to clarify the presence of
ring chromosome 22 and translocations. Parents shouldalso be tested for balanced rearrangement to assess recur-
rence risk in families. Sequencing of the SHANK3 gene is
necessary to identify mutations when CMA is unrevealing.
Although SHANK3 is understood to be the critical gene in
the deletion syndrome, responsible for the core pheno-
typic features of PMS [2-4,8,62,63], it is likely that other
deleted genes contribute to the severity and additional
phenotypic characteristics. Ongoing studies are focused
on exploring genotype-phenotype correlations, and should
relationships emerge, it may delineate a role for other
genes and pathways in PMS. Further, genotype-phenotype
associations may aid in medical monitoring and treatment
planning if larger deletion sizes are associated with specific
medical comorbidity or if greater impairments in language
or motor skills might be predicted from genotype.
Point mutations disrupting only SHANK3 have been de-
scribed in the literature and result in a similar phenotype,
including ASD and ID [2-4,7,37,64,65]. However, given
the small number of patients identified to date, the full
spectrum of phenotypic features has not clearly been de-
fined and whether these patients are at the same increased
risk of medical comorbidities as patients with deletions
that encompass many genes in the region remains an ac-
tive area of research. As whole exome and whole genome
sequencing become widespread, these approaches will
likely become the first line analyses in cases of unex-
plained developmental delay. It is estimated that the rates
of mutation of SHANK3 in ASD and developmental delay
are in the same range as deletions [66], so PMS due to
mutation in SHANK3 will be increasingly identified.
A thorough history and physical examination is clearly
the first step in evaluation. While there are several com-
mon medical and dysmorphic features, it does not appear
that, as of yet, any features are specific for the syndrome.
Neurological deficits are common in PMS. Motor deficits
in particular may affect the child’s feeding and ability to
thrive. The risk of seizures is greater in PMS and EEG is
recommended, especially when there is evidence of skill
regression. Given the prevalence of structural brain
abnormalities in PMS, including arachnoid cysts, there
should be a low threshold for performing brain imaging.
The identification of specific brain abnormalities in PMS
will aid in more thorough characterization and may pro-
vide a critical link between PMS and associated behavior.
Furthermore, the creation of an accurate brain phenotype
may be important for identifying biological markers of
disease progression and possibly treatment response in
the future. Endocrine, renal, cardiac, and gastrointestinal
problems have all been reported in PMS and require
assessment and monitoring. Other associated medical
features include recurring infections that require standard
management but may be more challenging to detect in
PMS. Few primary care or developmental pediatricians
have experience with PMS but will need to gain familiarity
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subspecialties. It is equally crucial for the developmental
pediatrician and other professionals involved in their care
to support the family in advocating for the child’s educa-
tional and emotional needs by making sure educators and
therapy providers understand the syndrome and its associ-
ated features. Appropriate referrals to specialists should be
initiated early and interventions implemented intensively.Table 3 Summary of clinical recommendations for assessmen
Medical specialty Common clinical features







Psychiatry Autism spectrum disorder
Psychology Aberrant behavior
Intellectual disability











Renal cysts, hypoplasia, or age




Primary care/developmental pediatrics Upper respiratory tract infectio
Recurring ear infections
Hearing and vision problems
Lymphedema
Dental problems
Decreased perspiration/heat inPediatric physiatry, physical therapy, occupational therapy,
and orthopedics are among the specialists to explore
the possibility of various interventions, including feeding
therapy, orthotics, and bracing. All patients require re-
ferrals to specialized centers for cognitive, behavioral,
and ASD evaluations (see Table 3).
Ongoing monitoring is crucial to track the disease




Chromosome analysis (to identify ring chromosomes)
Sanger or next generation sequencing (for mutations)
Fluorescence in situ hybridization (to identify balanced
rearrangements in parents)
Gold standard diagnostic assessments
Psychiatric evaluation
Cognitive and adaptive behavior testing
Speech and language evaluation
Overnight video electroencephalography
Brain imaging and head circumference monitoring
Feeding therapy evaluation
Occupational and physical therapy evaluations
Monitor height, weight, and body mass index
Metabolic work-up, including thyroid function
Nutritional assessment
Renal and bladder ultrasonography
Voiding cystourethrogram




Referral for dietary changes and/or medication
Bowel regimens
Referral to behavioral therapy
ns Careful and consistent monitoring and management
Referral to otolaryngology, ophthalmology, physiatry,
dental, and orthopedics
tolerance
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time points associated with increased risk of seizures,
for example, and repeated assessments are necessary in
suspected cases. In PMS, as patients age, they may be at
increased risk for atypical bipolar disorder [29,42,43],
and significant regression has also been reported in
language, behavioral symptoms, motor skills, and self-
help skills [2,29,37,42,43,62]. Isolated reports have also
emerged recently describing mortality associated with
complications of PMS, including seizure-induced aspir-
ation [2], renal failure in a patient with unilateral renal
agenesis [62], and pneumonia [42]. Awareness of the full
scope of medical comorbidity and aggressive monitoring
will be critical to ensure quality of life and survival of pa-
tients with PMS.
In summary, comprehensive assessment and regular
monitoring of patients with PMS across organ systems
are necessary to clarify the extent and severity of the
phenotype and to understand how PMS develops over
time. Appropriate evaluations may also provide import-
ant information on targets for early intervention and dis-
ease prevention in order to further develop the best
clinical practices. Establishing the natural history of PMS
is also a important step toward designing effective clin-
ical trials and may support the advancement of multiple
therapeutic possibilities in the future.
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